Gain Therapeutics (GANX)
NASDAQ:GANX
Top Page
Gain Therapeutics
(NASDAQ:GANX)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.50
▼(-23.47% Downside)
Action:ReiteratedDate:01/07/26
The score is mainly held back by weak financial performance (minimal revenue, significant losses, and ongoing cash burn). Technicals also lean negative in the near term (below 20D/50D with subdued momentum). A positive offset is the encouraging Phase 1b update and stated runway through year-end 2026, but valuation is constrained by negative earnings and no indicated dividend.
Positive Factors
Proprietary computational platform
A proprietary computational discovery platform is a durable competitive asset that can accelerate target identification and design across multiple programs. It can lower discovery costs, create repeatable pipeline opportunities, and support partnering/licensing strategies beyond any single asset.
Negative Factors
Minimal revenue and recurring losses
The company remains development-stage with virtually no commercial revenue and sizable recurring losses. This structural lack of revenue undermines margin sustainability, increases reliance on external capital, and limits internal funding for program expansion absent partnerships or financings.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary computational platform
A proprietary computational discovery platform is a durable competitive asset that can accelerate target identification and design across multiple programs. It can lower discovery costs, create repeatable pipeline opportunities, and support partnering/licensing strategies beyond any single asset.
Read all positive factors
Gain Therapeutics (GANX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$75.39M
Dividend YieldN/A
Average Volume (3M)809.86K
Price to Earnings (P/E)―
Beta (1Y)1.80
Revenue GrowthN/A
EPS Growth42.29%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding38,462,086
10 Day Avg. Volume973,233
30 Day Avg. Volume809,861
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)6.73
Price to Sales (P/S)0.00
P/FCF Ratio-2.62
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.46
Enterprise Value/Ebitda-3.00
Forecast
1Y Price Target
$6.67Price Target Upside240.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.71
Revenue Forecast (FY)N/A
Gain Therapeutics Business Overview & Revenue Model
Company Description
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enh...
How the Company Makes Money
Gain Therapeutics primarily makes money through partnerships, collaborations, and licensing agreements with larger pharmaceutical and biotechnology companies. These partnerships usually involve upfront payments, milestone payments based on the ach...
Gain Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 55.18K | 132.64K | 133.93K | 28.88K |
| Gross Profit | -4.99M | 0.00 | 55.18K | -8.11M | -7.03M | 28.88K |
| EBITDA | -17.40M | -20.27M | -22.17M | -17.76M | -13.82M | -3.47M |
| Net Income | -19.39M | -20.41M | -22.27M | -17.59M | -13.89M | -3.58M |
Balance Sheet | ||||||
| Total Assets | 10.97M | 12.12M | 18.61M | 24.10M | 38.99M | 9.60M |
| Cash, Cash Equivalents and Short-Term Investments | 8.81M | 10.39M | 16.79M | 20.14M | 36.88M | 7.49M |
| Total Debt | 605.28K | 653.01K | 1.03M | 1.27M | 1.61M | 1.26M |
| Total Liabilities | 5.06M | 4.78M | 6.03M | 5.22M | 4.17M | 3.40M |
| Stockholders Equity | 5.91M | 7.34M | 12.58M | 18.88M | 34.82M | 6.20M |
Cash Flow | ||||||
| Free Cash Flow | -17.30M | -18.90M | -18.88M | -14.81M | -12.46M | -3.26M |
| Operating Cash Flow | -17.30M | -18.87M | -18.87M | -14.69M | -12.37M | -3.24M |
| Investing Cash Flow | -43.45K | 4.98M | 10.22M | -14.77M | -94.21K | -20.83K |
| Financing Cash Flow | 14.21M | 13.01M | 12.64M | -78.77K | 41.77M | 10.49M |
Gain Therapeutics Technical Analysis
Negative
1.96
Price Trends
2.15
Negative
2.55
Negative
2.16
Negative
Market Momentum
-0.10
Positive
41.29
Neutral
8.64
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GANX, the sentiment is Negative. The current price of 1.96 is below the 20-day moving average (MA) of 2.45, below the 50-day MA of 2.15, and below the 200-day MA of 2.16, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 41.29 is Neutral, neither overbought nor oversold. The STOCH value of 8.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GANX.
Gain Therapeutics Risk Analysis
Gain Therapeutics disclosed 63 risk factors in its most recent earnings report. Gain Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Gain Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $205.39M | -2.24 | -129.98% | ― | 250.00% | 15.15% | |
53 Neutral | $73.06M | -0.84 | -59.07% | ― | ― | -58.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $75.39M | -2.93 | -341.33% | ― | ― | 42.29% | |
43 Neutral | $42.18M | -17.81 | 774.80% | ― | -8.16% | 22.44% | |
41 Neutral | $27.48M | -6.26 | -88.89% | ― | 56.52% | 75.22% |
* Healthcare Sector Average
GANX
Gain Therapeutics
1.89
-0.18
-8.70%
PSTV
Plus Therapeutics
0.24
-1.28
-84.08%
ABVC
ABVC BioPharma
1.06
0.26
32.50%
PMVP
PMV Pharmaceuticals
1.35
0.20
17.39%
PRLD
Prelude Therapeutics
3.24
2.56
376.47%
IMMX
Immix Biopharma
8.72
7.01
409.94%
Gain Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data
Positive
Dec 18, 2025
On December 18, 2025, Gain Therapeutics reported exploratory endpoint data from Part 1 of its Phase 1b clinical study of GT-02287 in people with Parkinson’s disease, showing that all participants with elevated cerebrospinal fluid glucosylsph...
Private Placements and FinancingRegulatory Filings and Compliance
Gain Therapeutics Announces New Stock Offering Program
Neutral
Nov 28, 2025
Gain Therapeutics, Inc., a company involved in the sale of common stock, announced on November 28, 2025, that it has filed a prospectus supplement with the SEC for an ‘at the market offering’ program. This program allows the company to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.